At a glance
- Originator Teijin Pharma
- Class Anti-ischaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 19 Jan 2000 New profile
- 19 Jan 2000 Preclinical development for Alzheimer's disease in Japan (Unknown route)